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Multiplicity and metachronous tumours are recurrent management problems. Morphological 
resemblance, in-situ carcinoma, cancer driver mutations, etc. have been used to distinguish 
intrapulmonary metastasis and metachronous primary lung cancers but these criteria are often 
insufficient. Next generation sequencing promises to advance personalized cancer management 
but finding a practicable approach remains a problem. We explored the utility of whole exome 
sequencing for cancer nature determination in a 74 year-old female non-smoker with 2 sequential 
lung cancers of unknown relation. Initially, she had an EGFR-L858R adenocarcinoma (Tumour-A) 
treated by excision and adjuvant gefitinib for metastatic pleural tumours. Two years later while 
still on gefitinib, she developed a contralateral, morphologically indistinguishable 
adenocarcinoma with no other metastasis (Tumour-B). 
Genetically, it was EGFR wild-type. We performed WES on formalin-fixed-paraffin-
embedded(FFPE) and frozen(FZ) tissues from each tumour with raw sequencing depths 240x 
(FFPE), and 150x(FZ/leukocytes control), respectively. Both tissue types yielded good quality 
data with no significant difference in on-target coverage or mutation type distribution, suggesting 
both are amenable to WES. Amongst 12108 significantly over-represented variants in tumours, 
<20% were common to both tumours-A and -B. The resistant EGFR-T790M genotype was 
undetected in either tumour. We further narrowed the candidate genes list using computational 
prediction (Condel) of exonic SNV effects on protein functions and compared mutation 
frequencies with lung adenocarcinomas registered in TCGA followed by Sanger sequencing for 
confirmation. Substitution mutations of POT1 (reported frequency 2.81%) and CKAP4 (1.80%) 
were proposed as cancer genes for tumour-B while POU6F2 (3.50%) might be involved in 
tumour-A. Using WES, we have shown tumour-B is likely a metachronous second primary or 
have developed through selection of metastatic bypass pathways. Various candidate genes are 
proposed as surveillance targets for tumour A or B, respectively. Further, those in tumour-B are 
likely resistant to tyrosine kinase inhibitors. 
